Kisspeptin-10

What it is

Kisspeptin-10 is the amidated ten-amino-acid human sequence YNWNSFGLRF. FDA maps it under UNII FS1N52VS3S with Human metastin 45–54; Kp-10 and KP-10 are shorthand. The sequence is exact even when the claims attached to it are not.

Kisspeptin-10 and Kisspeptin-54 are different exact substances. A Kisspeptin-10, Kp-10, Kisspeptin-10 acetate, or generic kisspeptin label does not establish exact form, formulation, purity, concentration, sterility, aggregation state, stability, handling, or equivalence across routes.

Why people care

Kisspeptin biology sits close to the body's reproductive-hormone signaling, so a short-lived LH or testosterone response can easily be retold as a fertility, low-testosterone, or libido treatment. The identified human studies are mainly small physiology experiments. They answer whether hormones moved under specific conditions—not whether people conceived, felt better, maintained a testosterone change, or benefited over time.

What humans actually show

• Healthy men: One experiment included six healthy men in an intravenous bolus study plus four-person infusion cohorts. Kisspeptin-10 produced rapid LH increases and changes in LH pulse frequency, burst mass, and testosterone. This was a very small physiology experiment with no fertility, symptom, libido, or long-term outcome.
• Men and women across cycle phases: Groups of four to five healthy participants received intravenous or subcutaneous Kisspeptin-10. Men showed gonadotropin responses; women in the follicular phase did not show changes under the tested conditions, while women in the preovulatory phase did. The result is acute, small, and cycle-phase dependent—not a pregnancy or fertility trial.
• Men with type 2 diabetes and mild biochemical hypogonadism: The study included five affected men and seven healthy comparators; four affected men entered the infusion experiment. LH and testosterone increased during short bolus and infusion experiments. It did not test sustained testosterone, symptoms, sperm, pregnancy, or libido.
• Rare neurokinin-B signaling deficiencies: Four people with TAC3 or TACR3 loss-of-function mutations received continuous intravenous Kisspeptin-10. The study reported restoration or increases in pulsatile LH secretion during infusion. This rare genotype-defined physiology result does not generalize to broader secondary hypogonadism.
• Twenty-four-hour infusion: A 2026 study included three healthy adult men. LH rose substantially and then declined from its maximum while remaining above baseline; FSH and testosterone rose modestly. Three healthy participants and hormone measurements do not establish treatment effectiveness or chronic safety.

Mechanistic and nonhuman evidence

Rat and ex-vivo hypothalamic experiments found that Kisspeptin-10 stimulated GnRH and LH signaling and implicated several intracellular pathways. This helps explain the acute hormone-response studies. It does not establish human fertility, symptom, libido, or long-term treatment benefit and does not authenticate a product.

FDA and U.S. status

FDA placed Kisspeptin-10 in category 2 under its 503A interim policy on September 29, 2023, reflecting the agency's identification of potential significant safety risks during the nomination review. FDA's Pharmacy Compounding Advisory Committee later voted 0 yes, 11 no, and 0 abstain on placing Kisspeptin-10 on the 503A Bulks List. FDA's briefing states that the agency would not issue a final determination until the advisory process and reviews were complete. No later final action was identified in the official sources searched for this profile.

Category-2 interim placement and the advisory compounding vote are not drug approval, a blanket ban, final list action, or a product-quality finding about an unidentified material. An exact-active-ingredient Drugs@FDA search returned no match in the dated source pass, but PepCurrent does not convert that database result into a broader legal conclusion.

Risks and warning limits

FDA's briefing found no serious adverse events in the small short-duration human studies, but emphasized the limited samples, short exposure, frequent missing adverse-event reporting, and absence of a chronic or fixed-schedule safety trial beyond one day.

FDA also recorded one limited FAERS report of weight gain and increased estrone after a compounded subcutaneous product in a 17-year-old. FDA said the temporal relationship was unclear and the clinical information insufficient, so causality and frequency cannot be inferred.

FDA describes unresolved aggregation, peptide-impurity, immunogenicity, and possible endogenous-peptide cross-neutralization concerns and found no formal immunogenicity study. There is no complete approved-product label defining contraindications, pregnancy effects, rare events, or interactions for Kisspeptin-10.

What remains unknown

• The final FDA administrative disposition after the 2024 advisory vote.
• Whether Kisspeptin-10 improves symptoms, sperm parameters, pregnancy, sustained testosterone, libido, or quality of life.
• Chronic safety, immunogenicity, contraindications, pregnancy effects, and treatment-interaction risks.
• Whether the three-person 2026 hormone pattern replicates in a larger controlled study.
• The exact identity and quality of any nonstudy product.

Product identity and quality limits

FDA's briefing recorded an initial mismatch between a Kisspeptin-10 nomination and a Kisspeptin-10 acetate certificate of analysis. That illustrates why exact form cannot be inferred from a shared name.

A Kisspeptin-10, Kp-10, Kisspeptin-10 acetate, or generic kisspeptin label does not establish exact form, sequence, purity, concentration, sterility, aggregation state, stability, or handling. Kisspeptin-54 outcomes cannot be assigned to Kisspeptin-10 without an explicit exact-substance bridge.

What has been studied together

The identified literature mainly uses Kisspeptin-10 as an endocrine probe. No adequate direct human treatment-interaction program with testosterone, hCG, fertility drugs, or other peptides was identified. Missing evidence does not establish compatibility or safety.

What people are hearing

• “An acute LH or testosterone rise proves Kisspeptin-10 treats low testosterone or libido.” A hormone response is not a sustained clinical outcome.
• “Kisspeptin-54 fertility or pregnancy results apply to Kisspeptin-10.” These are different exact substances; transfer requires an explicit evidence bridge.
• “The 2024 advisory vote was a final FDA ban or drug-approval decision.” It was a recommendation about one compounding-policy list, not final administrative action or drug approval.

Questions readers raise

Readers ask whether a short hormone rise means treatment, whether all kisspeptins are interchangeable, and whether the advisory vote settled every legal question. These are questions to investigate, not evidence of efficacy, safety, approval, final FDA action, or product identity. PepCurrent has not published anecdotal theme counts or public user reviews for this profile.

What would change this answer

• A final FDA administrative action after the PCAC recommendation.
• An adequately powered controlled trial in a defined disorder with patient-important reproductive outcomes and complete adverse-event reporting.
• Formal product-specific immunogenicity, stability, impurity, and manufacturing evidence.
• A validated exact-substance bridge before using Kisspeptin-54 outcomes for a Kisspeptin-10 conclusion.

Sources and records

• WADA — 2026 Prohibited List

• FDA UNII record for Kisspeptin-10
• FDA compounding substances with potential significant safety risks
• FDA Kisspeptin-10 briefing document
• October 29, 2024 PCAC meeting page
• October 29, 2024 PCAC final summary minutes
• Drugs@FDA exact active-ingredient API search
• ClinicalTrials.gov Kisspeptin-10 intervention search
• Healthy-men physiology study — PMID 21632807
• Sex-dimorphism study — PMID 21976724
• Type 2 diabetes and mild biochemical hypogonadism study — PMID 23153270
• Neurokinin-B signaling-deficiency study — PMID 22377698
• Twenty-four-hour infusion study — PMID 42230485
• Rat mechanism study — PMID 16930819